Inozyme Pharma (ITOS) Upgraded by Zacks Investment Research to Buy

Inozyme Pharma stock has undergone multiple analysts rating changes in the recent past.  Inozyme Pharma Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of Inozyme Pharma traded down -$0.30 on Tuesday, reaching $9.89. 0 shares of the stock traded hands, compared to its average volume of 139060. Shares of Inozyme Pharma were trading at $9.89 on Tuesday. The firm’s 50 day moving average is $26.82 and its 200 day moving average is $28.63.Inozyme Pharma has a 12 month low of $9.88 and a 12 month high of $29.46. While on yearly highs and lows, Inozyme Pharma’s today has traded high as $10.75 and has touched $9.88 on the downward trend. See More Analyst Rating at: RATING

Inozyme Pharma Earnings and What to expect: 

iTeos Therapeutics last released its earnings data on August 12th, 2021. The reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.34. iTeos Therapeutics has generated ($2.88) earnings per share over the last year (($2.05) diluted earnings per share). Earnings for iTeos Therapeutics are expected to decrease in the coming year, from $3.22 to ($3.12) per share. iTeos Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for iTeos Therapeutics are expected to decrease in the coming year, from $3.22 to ($3.12) per share. The P/E ratio of iTeos Therapeutics is -13.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of iTeos Therapeutics is -13.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. iTeos Therapeutics has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Inozyme Pharma (ITOS) Moving Average Technical Analysis

5 day Moving Average is $26.62 And 5 day price change is $0.01 (0.04%)  with average volume for 5 day average is 126,880. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $27.12 and 20 day price change is -$0.82 (-2.98%) and average 20 day moving volume is 152,925. 50 day moving average is $26.82  and 50 day price change is $1.98 ( 8.02%)  and with average volume for 50 days is : 169,890. 200 day moving average is $28.63  and 200 day price change is -$6.67 (-20.01%)  and with average volume for 200 days is : 311,100.

Other owners latest trading in Inozyme Pharma :

  • On 8/25/2021 shares held by Marshall Wace LLP were 142,929 which equates to market value of $3.67M and appx 0.00% owners of Inozyme Pharma
  • On 8/25/2021 shares held by Marshall Wace North America L.P. were 211,095 which equates to market value of $5.42M and appx 0.00% owners of Inozyme Pharma
  • On 8/23/2021 shares held by Morgan Stanley were 91,352 which equates to market value of $2.34M and appx 0.00% owners of Inozyme Pharma
  • In total Institutional ownership equates to Institutional Ownership Percentage: 83.69% for Inozyme Pharma

See More Analyst Rating at: RATING